Extracellular matrix degrading enzyme with stroma-targeting peptides enhance the penetration of liposomes into tumors

Ikeda‐Imafuku, Mayumi; Gao, Yongsheng; Shaha, Suyog; Wang, Lily Li‐Wen; Park, Kyong Soo; Nakajima, Mayuka; Adebowale, Omokolade; Mitragotri, Samir

doi:10.1016/j.jconrel.2022.11.007

Cited by 11 publications

(9 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…167 Bromelain has been delivered using liposomes, solid lipid nanoparticles, polymeric nanoparticles and nanostructured lipid carriers. 166,168,169 The selection of suitable materials for the development of bromelain nanoformulations is another factor that needs consideration. 170 These materials can affect the stability of the formulation as well as the efficacy, bioavailability and safety of bromelain.…”

Section: Food and Function Reviewmentioning

confidence: 99%

Bromelain: a review of its mechanisms, pharmacological effects and potential applications

Kumar¹,

Mangla²,

Javed³

et al. 2023

Food Funct.

View full text Add to dashboard Cite

show abstract

Section: Food and Function Reviewmentioning

confidence: 99%

Bromelain: a review of its mechanisms, pharmacological effects and potential applications

Kumar¹,

Mangla²,

Javed³

et al. 2023

Food Funct.

View full text Add to dashboard Cite

show abstract

“…After administration of C4BP−HA−Bro, the tumor penetration and antitumor efficacy of liposomal doxorubicin were promoted. 59 HA was also a major component of tumor ECM, increasing tumor stiffness and limiting drug diffusion. 60 To reduce HA and modulate tumor mechanics, recombinant human hyaluronidase PH20 (rHuPH20) was conjugated onto the surface of PLGA−PEG nanoparticles and protected by a relatively low density layer of PEG for prolonged blood circulation.…”

Section: ■ Modulating Tumor Mechanicsmentioning

confidence: 99%

“…Bromelain, another enzyme for ECM degradation by decreasing the amount and length of collagen, was conjugated to hyaluronic acid (HA) and further modified with ECM-targeted collagen type IV-binding peptide (C4BP), to obtain C4BP–HA–Bro. After administration of C4BP–HA–Bro, the tumor penetration and antitumor efficacy of liposomal doxorubicin were promoted . HA was also a major component of tumor ECM, increasing tumor stiffness and limiting drug diffusion .…”

Section: Modulating Tumor Mechanicsmentioning

confidence: 99%

Tumor Mechanics Meets Nanomedicine Mechanical Properties

Li,

Yang,

2024

Chem. Mater.

View full text Add to dashboard Cite

While small molecule drugs have gained benefits in tumor targeting delivery from their nanotherapeutic formulation, the antitumor efficacy of nanomedicines is jointly determined by tumor mechanics and nanomedicine mechanical properties. In this Perspective, we summarize different strategies for modulating tumor mechanics and three typical nanomedicines with distinct mechanical properties. Most importantly, the matching between tumor mechanics and nanomedicine mechanical properties is discussed, providing guidance for the rational design and efficient clinical application of nanomedicines.

show abstract

“…[77] The dense extracellular matrix can hinder nanocarrier penetration, reducing anticancer therapeutic efficacy. [78] ONOO − could degrade the dense extracellular matrix via activating the promatrix metalloproteinases (pro-MPs) to generate matrix metalloproteinases (MMPs), which further boosted the penetration of micelles. [79,80] ONOO − and nitric oxide could impair mitochondrial function by decreasing mitochondrial membrane potential and hindering the production of adenosine triphosphate (ATP), inhibiting ATP-dependent tumor-derived microvesicles (TMVs) and suppressing tumor metastasis.…”

Section: Nitric Oxide-releasing Nanocarriersmentioning

confidence: 99%

Tailored Beta‐Lapachone Nanomedicines for Cancer‐Specific Therapy

Feng

Guo

Wang

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Nanotechnology shows the power to improve efficacy and reduce the adverse effects of anticancer agents. As a quinone‐containing compound, beta‐lapachone (LAP) is widely employed for targeted anticancer therapy under hypoxia. The principal mechanism of LAP‐mediated cytotoxicity is believed due to the continuous generation of reactive oxygen species with the aid of NAD(P)H: quinone oxidoreductase 1 (NQO1). The cancer selectivity of LAP relies on the difference between NQO1 expression in tumors and that in healthy organs. Despite this, the clinical translation of LAP faces the problem of narrow therapeutic window that is challenging for dose regimen design. Herein, the multifaceted anticancer mechanism of LAP is briefly introduced, the advance of nanocarriers for LAP delivery is reviewed, and the combinational delivery approaches to enhance LAP potency in recent years are summarized. The mechanisms by which nanosystems boost LAP efficacy, including tumor targeting, cellular uptake enhancement, controlled cargo release, enhanced Fenton or Fenton‐like reaction, and multidrug synergism, are also presented. The problems of LAP anticancer nanomedicines and the prospective solutions are discussed. The current review may help to unlock the potential of cancer‐specific LAP therapy and speed up its clinical translation.

show abstract

Extracellular matrix degrading enzyme with stroma-targeting peptides enhance the penetration of liposomes into tumors

Cited by 11 publications

References 54 publications

Bromelain: a review of its mechanisms, pharmacological effects and potential applications

Bromelain: a review of its mechanisms, pharmacological effects and potential applications

Tumor Mechanics Meets Nanomedicine Mechanical Properties

Tailored Beta‐Lapachone Nanomedicines for Cancer‐Specific Therapy

Contact Info

Product

Resources

About